<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136857">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319695</url>
  </required_header>
  <id_info>
    <org_study_id>1234560</org_study_id>
    <nct_id>NCT01319695</nct_id>
  </id_info>
  <brief_title>Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <brief_summary>
    <textblock>
      The use of corifollitropin alfa is superior in terms of pregnancy outcome parameters as
      compared to recombinant follicle stimulating hormone (FSH) during ovarian stimulation
      protocols in women undergoing in vitro fertilisation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>no of oocytes (&gt;2 between groups)</measure>
    <time_frame>at egg recovery, through study completion, an average of 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate cancellation rate miscarriage rate ectopic pregnancy rate</measure>
    <time_frame>3 weeks after embryo transfer</time_frame>
    <description>The presence of fetal heart at transvaginal ultrasound at 6+2 gestational weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 weeks after embryo transfer</time_frame>
    <description>The presence of fetal heart at ultrasound after 12 gestational weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miscarriage rate</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>live birth rate</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>corifollitropin alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>recombinant follicle stimulating hormone (FSH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150-300 IU of FSH for ovarian stimulation in women undergoing IVF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corifollitropin alfa</intervention_name>
    <description>100 microg for a group of women weighing &lt;or=60 kg and 150 microg for a group of women weighing &gt;60 kg</description>
    <arm_group_label>corifollitropin alfa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant follicle stimulating hormone (FSH)</intervention_name>
    <description>150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are &gt;18mm</description>
    <arm_group_label>recombinant follicle stimulating hormone (FSH)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18-36 years old with a body weight of more than 60 kg up to 90 kg

          -  BMI of 18-32 kg/m2

          -  Menstrual cycle length of 23-35 days

          -  An indication for controlled ovarian stimulation for IVF or ICSI

        Exclusion Criteria:

          -  history of an endocrine abnormality

          -  abnormal outcome of blood biochemistry or hematology

          -  abnormal cervical smear

          -  chronic disease

          -  uterine pathology that interfering with the COS treatment (e.g. fibroids â‰¥ 5 cm)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charalampos S Siristatidis, MD,PhD</last_name>
    <phone>6932294994</phone>
    <phone_ext>0030</phone_ext>
    <email>harrysiri@yahoo.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>3rd Department of Obstetrics and Gynecology, Assisted Reproduction Unit</name>
      <address>
        <city>Athens</city>
        <state>Chaidari</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlampos Siristatidis</last_name>
      <email>harrysiri@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Charalampos Chrelias, Assistant Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Demetrios Kassanos, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <state>Chaidari</state>
        <zip>12642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siristatidis, Assistant Professor</last_name>
      <email>harrysiri@yahoo.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 6, 2016</lastchanged_date>
  <firstreceived_date>March 8, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Siristatidis Charalampos, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor, Director of the ARU</investigator_title>
  </responsible_party>
  <keyword>corifollitropin alfa</keyword>
  <keyword>FSH ovarian stimulation</keyword>
  <keyword>IVF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
